Oric Pharmaceuticals
Steve Hoerter is an accomplished executive with extensive experience in the pharmaceutical industry. Currently serving as President and CEO at Deciphera Pharmaceuticals since May 2018, Steve also holds a position on the Board of Directors for ORIC Pharmaceuticals Inc. and Constellation Pharmaceuticals. Previously, Steve has contributed to several organizations, including Agios Pharmaceuticals as Chief Commercial Officer and Clovis Oncology in multiple senior commercial roles. Steve’s notable career includes leadership positions at Roche and Genentech, as well as a series of marketing and sales roles at Eli Lilly. Steve holds a BA from Bucknell University, an MS in Management from Purdue University, and an MBA from Tilburg University.
This person is not in the org chart
This person is not in any offices
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.